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Abstract
 
The expression of the pre-T cell receptor 
 
 
 
 (
 
pTa
 
) gene occurs exclusively in immature T lym-
phocytes and is regulated by poorly defined mechanisms. We have analyzed the role of the up-
stream enhancer in 
 
pTa
 
 expression using conventional and bacterial artificial chromosome
(BAC) reporter transgenes. The deletion of the enhancer completely abolished the expression
of 
 
pTa
 
 BAC reporter in transgenic mice. Conversely, the combination of 
 
pTa
 
 enhancer and
promoter targeted transgenes specifically to immature thymocytes, recapitulating the expression
pattern of 
 
pTa
 
. The core enhancer is conserved between mice and humans and contains a crit-
ical binding site for the transcription factor c-Myb. We also show that 
 
pTa
 
 promoter contains a
conserved tandem E box site activated by E protein, HEB. These data establish the enhancer as
a critical element regulating 
 
pTa
 
 gene expression and identify additional targets for c-Myb and
E proteins in T cell development.
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Introduction
 
The development of T lymphocytes involves multiple steps
of progressive cellular differentiation, selection and lineage
commitment. Several of these steps occur at the earliest
CD4
 
 
 
CD8
 
 
 
 (double-negative [DN])
 
*
 
 stage of T cell de-
velopment in the thymus (1, 2). First, thymic progenitors
undergo full commitment to the T cell lineage and start re-
arrangement of the TCR
 
 
 
, 
 
 
 
, and 
 
 
 
 genes. Second, T cells
with productive TCR
 
 
 
 rearrangement receive a selective
survival signal from the pre-TCR at the so called 
 
 
 
-selec-
tion checkpoint. Finally, the choice is made between the
predominant T cell lineage expressing 
 
 
 
/
 
 
 
 TCR, and a
specialized population of T cells expressing 
 
 
 
/
 
 
 
 TCR. De-
spite recent advances (3, 4), transcriptional mechanisms
regulating these processes are not fully understood.
Commitment to the T cell lineage depends on several
transcription factors including GATA-3 (5) and c-Myb (6).
C-Myb is expressed in immature hematopoietic cells (7)
and has been shown to activate several T cell–specific regu-
latory elements (8–13). Recently, it was demonstrated that
T cell lineage commitment requires a signal from Notch
receptors (14, 15) and their downstream effector Hes1 (16).
Furthermore, T cell commitment requires the activity of
basic helix-loop-helix (bHLH) transcription factors (17). In
particular, bHLH proteins E2A and HEB regulate early T
cell development at multiple steps (18, 19). Members of the
E protein family of bHLH factors, these proteins bind their
target E box (CANNTG) elements as homo- or het-
erodimers, and are abundantly expressed in thymocytes
(20). In addition to their role in T cell commitment, Notch
signaling and E proteins activity appear to favor 
 
 
 
/
 
 
 
 over
 
 
 
/
 
 
 
 T cell development (21, 22). The identification of tar-
get genes and regulatory sites for these factors should estab-
lish the molecular basis of lineage commitment and stage-
specific gene expression in T cell development.
The pre-TCR
 
 
 
 (
 
pTa
 
) gene encodes a critical compo-
nent of the pre-TCR complex in DN thymocytes under-
going 
 
 
 
-selection (1). Signaling from the pre-TCR is re-
quired for the expansion of T cells with functional TCR
 
 
 
products and for efficient TCR
 
 
 
 allelic exclusion, and is
thought to promote commitment to the 
 
 
 
/
 
 
 
 T cell lineage
(23). Consistent with its function, the expression of 
 
pTa
 
 is
restricted to immature T cells in the thymus and in ex-
trathymic sites of T cell development (24, 25). In the thy-
mus, 
 
pTa
 
 expression is highest in the DN population and
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decreases during differentiation into immature CD8
 
 
 
 sin-
gle-positive (ISP) and then into CD4
 
 
 
CD8
 
 
 
 double-posi-
tive (DP) thymocytes. Subsequently, 
 
pTa
 
 expression is
silenced at the transition to mature single-positive (SP) thy-
mocytes and is absent from mature peripheral T cells or
other cell types. Within the DN thymocyte subset, 
 
pTa
 
 is
expressed at low levels in uncommitted thymic CD44
 
 
 
CD25
 
 
 
 (DN1) precursors. The major upregulation of 
 
pTa
 
message coincides with commitment to T cell lineage at
the CD44
 
 
 
CD25
 
 
 
 (DN2) stage (2, 24). The expression
reaches its peak in CD25
 
 
 
CD44
 
 
 
 (DN3) cells undergoing
 
 
 
-selection and is downregulated in CD25
 
 
 
CD44
 
 
 
 (DN4)
postselection thymocytes. Therefore, the expression of 
 
pTa
 
may serve as a marker and possibly one of the determinants
of T cell commitment, representing an important model
for the transcriptional regulation of early T call develop-
ment.
Consistent with this notion, 
 
pTa
 
 was recently shown to
be upregulated by Notch signaling (26) and by E proteins
(22), particularly by HEB (27). However, the mechanism
of these and other aspects of 
 
pTa
 
 transcriptional regulation
remains to be investigated. To address this issue, we sought
to identify elements responsible for tissue- and stage-spe-
cific expression of 
 
pTa
 
, as well as important regulatory sites
within these elements. We previously reported that the ge-
nomic region upstream of the mouse 
 
pTa
 
 gene contains
specific DNase-hypersensitive sites and targets transgene
expression to the thymus. Within this region, we identified
a proximal promoter and an enhancer element located 4 kb
upstream of the promoter (28). We now report that the en-
hancer is a critical element regulating 
 
pTa
 
 expression in im-
mature T cells. We also identify conserved functional sites
in the enhancer and promoter that are activated by c-Myb
and HEB, respectively. These findings begin to establish
the molecular basis for the cell- and stage-specific expres-
sion of 
 
pTa
 
.
 
Materials and Methods
 
Transgenic Constructs.
 
A 160-kb bacterial artificial chromo-
some
 
 (
 
BAC) clone containing the mouse 
 
pTa
 
 locus was modified
using ET recombination as described by Stewart and colleagues
(29) using the reagents provided by the authors. A fragment of
the first 
 
pTa
 
 exon including part of the 5
 
 
 
 UTR, the initiation
codon and most of the coding sequence (positions 570–651 of
GenBank/EMBL/DDBJ entry U27268) was replaced by a frag-
ment containing enhanced green fluorescent protein (
 
EGFP
 
;
CLONTECH Laboratories, Inc.), 
 
BGH
 
 polyA signal, and an
EM7-
 
Sh ble
 
 prokaryotic 
 
Zeo
 
r
 
 cassette (Invitrogen) flanked by
FRT sites. The 
 
Zeo
 
r
 
 cassette was subsequently removed using
FLP-expressing bacterial strain 294-FLP. In the second round of
recombination, the 
 
pTa
 
 upstream enhancer fragment (positions
1,366–1,697 of GenBank/EMBL/DDBJ entry AF132612) was
replaced by the 
 
Zeo
 
r
 
 cassette. Correct targeting and integrity of
the BAC clones were confirmed by PCR and restriction analysis
using conventional and pulsed-field gel electrophoresis. The
 
EGFP
 
-containing BAC clones were digested with NotI, which
released an 85-kb fragment containing 30 kb 5
 
 
 
 and 45 kb 3
 
 
 
 of
the 
 
pTa
 
 gene as determined by long-range mapping.
 
The enh-EGFP reporter construct contained the following
fragments assembled in pBluescript: two 1.2-kb chicken 
 
 
 
-globin
insulator fragments (30); a 1.9-kb XbaI-EcoRI 
 
pTa
 
 enhancer
fragment; a 0.27-kb 
 
pTa
 
 promoter fragment; 
 
EGFP
 
 gene; and
 
BGH
 
 polyA signal. For the enh/Amut-EGFP construct, the mu-
tation depicted in Fig. 5 A was introduced into the enhancer
fragment before subcloning using QuikChange system (Strat-
agene), and verified by sequencing. The constructs were linear-
ized with XhoI and NotI and purified from the vector backbone.
For the 
 
hCD25
 
-based reporter constructs, the following frag-
ments were assembled using the SalI-SmaI fragment of p
 
 
 
Gal
vectors (CLONTECH Laboratories, Inc.) as a backbone: a 2.8-
kb XbaI or a 0.25-kb BstEII-MluNI fragment containing 
 
pTa
 
enhancer; a 0.5-kb HindIII-PstI 
 
pTa
 
 promoter fragment; and a
3-kb BamHI-SalI fragment of pKCR.H-2Kd.hIL-2R vector
containing 
 
hCD25
 
 cDNA within a promoterless 
 
 
 
-globin exon-
intron structure (31). The resulting constructs were linearized
with SalI.
 
Analysis of Transgenic Mice.
 
The constructs were microin-
jected into fertilized oocytes of FVB mice, and transgenic off-
spring were identified by PCR using primers specific for 
 
EGFP
 
or 
 
hCD25
 
. Transgene copy number was determined by South-
ern hybridization of BamHI-digested genomic DNA with 
 
pTa
 
promoter probe detecting germline and transgenic fragments of
different size. Transgenic founders were analyzed directly, ex-
cept for BAC transgenes, in which case hemizygous F1 animals
were analyzed.
The lymphoid cells from transgenic mice were stained with di-
rect antibody conjugates and analyzed using a FACSCalibur™
flow cytometer (BD PharMingen). For the analysis of EGFP ex-
pression, thymocytes were stained with mAb to CD3 (PE), CD8
(peridinine chlorophyll protein [PerCP]), and CD4 (allophycocy-
anin [APC]). For the analysis of EGFP expression in DN thy-
mocyte subsets, cells were stained with mAb to CD25 (PE),
CD44 (Cy-Chrome), and a cocktail of mAb to CD3, CD4,
CD8, B220, and Mac-1 (APC). Splenocytes were stained with
mAb to CD3 (PE) and B220 (APC). Bone marrow cells were
stained with mAb to CD19 (PE) and B220 (APC). For the analy-
sis of hCD25 expression, lymphocytes were stained with mAb to
hCD25 (PE) and CD3 or B220 (FITC), or with mAb to hCD25
(APC), CD4 (PE), and CD8 (FITC).
 
Reporter Constructs.
 
A 0.15-kb PpuMI-PstI 
 
pTa
 
 promoter
fragment or a 0.45-kb CD3
 
 
 
 promoter (32) were cloned into the
promoterless 
 
 
 
-galactosidase (
 
LacZ
 
) reporter vector p
 
 
 
Gal-Basic
(CLONTECH Laboratories, Inc.). In other constructs, tested
fragments were inserted into the p
 
 
 
Gal-promoter vector up-
stream of the SV40 early promoter and 
 
LacZ
 
. These included a
0.25-kb BstEII-MluNI 
 
pTa
 
 enhancer fragment, a 0.6-kb CD3
 
 
 
enhancer fragment (32), and oligonucleotides containing one or
four copies of the 17-bp 
 
pTa
 
 enhancer site A (GACAGGCA-
GAGTCGTTA). Four copies of the 13-bp site A (GGCA-
GAGTCGTTA), either native or containing a mutation shown
on Fig. 5 A, were inserted upstream of the SV40 TATA box and
luciferase reporter in a modified pGL3-Basic luciferase reporter
vector (Promega).
The following deletion fragments of the BstEII-MluNI en-
hancer (28) were used: 82–257 (a full-strength core fragment);
101–257 (deletion of the 5
 
 
 
 enhancer site); and 1–158 (a partially
disabled fragment truncated at the 3
 
 
 
 end). A 0.3-kb human 
 
pTa
 
enhancer fragment (position 39,422–39,728 of GenBank/
EMBL/DDBJ entry HS475N16) was amplified by PCR from
BAC clone RP3–475N16 (Research Genetics). Site-directed
mutagenesis of promoter and enhancer fragments within reporter 
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constructs was performed using QuikChange system, and the re-
sulting constructs were verified by sequencing. Full-length mouse
c-Myb or human HEB cDNA were cloned into the pCAGGS
mammalian expression vector (33).
 
Transfection and Reporter Assays.
 
Cell lines LR1 (
 
pTa
 
-positive
pre-T cell lymphoma; reference 28) and BW5147 (
 
pTa
 
-negative
T cell lymphoma) were transfected in duplicate using Fugene 6
reagent (Roche Molecular Biochemicals). The 
 
 
 
-galactosidase
and/or luciferase activities were determined 24 h later using the
corresponding chemiluminescent assays (Tropix). The ranges of
duplicate samples were  15% of mean values. Data represent ei-
ther mean cpm   range or the ratio of mean cpm values. For the
cotransfection experiments, LR1 cells were transfected with a
 -galactosidase reporter construct, the expression vector (HEB or
empty vector), and pGL3-control luciferase expression vector
(Promega). The activity of  -galactosidase was normalized by the
luciferase activity in the same lysates.
For stable transfection, BW5147 cells were electroporated in
the presence of linearized pCAGGS/c-Myb and neor cassette vec-
tor KT3NP4 at a 10:1 ratio. After 2 d of culture, cells were se-
lected in the presence of 1 mg/ml G418 in 96-well plates, and in-
dividual clones were expanded. For the detection of c-Myb
protein, total cell lysates prepared from 5   105 cells were ana-
lyzed by Western blotting using the c-Myb polyclonal antibody
M-19 (Santa Cruz Biotechnology, Inc.).
Electrophoretic Mobility Shift Assay. The assay was performed
as described (28). A fragment of c-Myb cDNA encoding the
complete DNA binding domain (amino acids 22–203 of c-Myb)
was amplified by PCR and cloned in-frame with a V5 epitope
tag and B42 activation domain into the pYESTrp2 vector (Invit-
rogen) downstream of the T7 promoter. This construct or the
pYESTrp2 vector alone was translated in vitro using the T7 TnT
reticulocyte lysate system (Promega). The integrity and size of the
translation products were confirmed by Western blotting using an
anti-V5 antibody (Invitrogen). Double-stranded oligonucleotide
probes included a synthetic consensus c-Myb binding site (Santa
Cruz Biotechnology, Inc.), pTa enhancer site A (three different
probes containing site A sequence GACAGGCAGAGTCGTTA
were used with similar results) or mutated site A (GACAGGCA-
GAGTCGACAGGGACACCTGCCTC).
Results
The Upstream Enhancer Is Necessary for pTa Expression.
To explore the role of the upstream enhancer in pTa ex-
pression, we used a recently developed approach based on
bacterial artificial chromosome (BAC) modification by ho-
mologous recombination. To create a reporter reflecting
pTa locus transcription, we introduced the gene for EGFP
into the first exon of the mouse pTa locus in a BAC clone
(Fig. 1 A). Subsequenty, we replaced the core 0.3 kb up-
stream enhancer with a 0.45-kb prokaryotic Zeocin resis-
tance (Zeor) cassette. As the Zeor fragment lacks any eukary-
otic regulatory sequences, it is unlikely to interfere with the
transcription of pTa locus in cells. The EGFP-modified
BAC fragments with or without the enhancer deletion
(constructs BAC-EGFP and BAC enh-EGFP, respec-
tively) were injected into mice, and transgenic progeny
were analyzed for EGFP expression by flow cytometry.
Fig. 1 B illustrates EGFP expression in DN3 thymocytes,
which represent the primary pTa-expressing population
(24). In the lines carrying a wild-type BAC transgene mod-
ified with EGFP, we observed homogeneous EGFP ex-
pression with the levels proportional to the transgene copy
number. In contrast, no EGFP signal was detected in DN3
cells or any other lymphocyte population in transgenic lines
lacking the enhancer. All in all, four transgenic lines were
examined for each construct, yielding the same results. A
similar replacement of another region upstream of pTa had
no effect on EGFP expression in thymocytes, thus ruling
out any nonspecific effect of Zeor cassette insertion (unpub-
Figure 1. Transgenic analysis of the pTa enhancer function. (A) Map of the pTa locus and of the transgenic constructs used. The coding regions, UTR
and the upstream enhancer of pTa are shown as black, white, and dark gray boxes, respectively. All constructs contained a reporter cassette consisting of
EGFP cDNA (light gray box) and polyadenylation signal (EGFP-pA). The conventional transgenic construct (enh-EGFP) contained pTa enhancer and
promoter fragments flanked at the 5  end by two copies of the chicken  -globin insulator element (arrows). In the BAC modification scheme, EGFP-pA
was introduced into the first pTa exon within a BAC clone. The resulting BAC fragment was used as a 85-kb transgene (BAC-EGFP) or further modi-
fied to yield construct BAC enh-EGFP, in which a 0.3 kb upstream enhancer fragment was replaced by a 0.45-kb prokaryotic Zeor cassette (hatched
box). (B) Expression of the EGFP reporter in thymocytes of BAC transgenic mice. Thymocytes were analyzed by four-color flow cytometry, and histo-
grams of green fluorescence in DN3 subset are shown. The progeny of three independent transgenic lines for each construct were analyzed along with a
nontransgenic mouse (control); transgene copy number of each line is indicated.982 The Analysis of pTa Enhancer
lished data). We therefore conclude that the upstream en-
hancer is indispensable for the expression of the pTa locus
in developing thymocytes.
The Enhancer and Promoter Recapitulate the Expression Pat-
tern of pTa. In a complementary approach, we created a
conventional transgenic construct containing pTa enhancer
and promoter fragments upstream of EGFP (construct enh-
EGFP in Fig. 1 A). Our previous studies revealed that the
upstream pTa region is subject to position effects in trans-
genic mice, resulting in a low frequency of founders ex-
pressing the transgene (28). To blunt the effects of trans-
gene integration site, we included two chicken  -globin
insulator elements at the 5  end of the construct. The insu-
lator elements are thought to facilitate the expression of a
transgene by blocking the silencing effects of neighboring
heterochromatin (30). Indeed, EGFP expression was de-
tected in the thymuses of all six enh-EGFP founders exam-
ined, four founders demonstrating high expression levels
(Table I). Although heterocellular expression reminiscent
of position-effect variegation (34) was observed in enh-
EGFP transgenic mice, all founders exhibited a similar pat-
tern of EGFP expression in lymphocyte subsets.
Fig. 2 illustrates the expression in a representative
founder (founder V in Table I) in comparison to the BAC-
EGFP transgenic mouse. The BAC enh-EGFP transgenic
mice lacked any detectable EGFP expression in any lym-
phocyte subset, and a representative expression profile is
shown as a negative control. As shown in the figure, the
expression patterns of enh-EGFP and BAC-EGFP con-
structs were essentially identical and consistent with the ex-
pression of pTa itself. Within the DN thymocyte subset,
the expression was low and heterogeneous in the earliest
DN1 T cell precursors, then was upregulated in committed
DN2 T cells, reached the highest level in the DN3 subset
and decreased afterwards. Within the T cell lineage, the ex-
pression was the highest in DN thymocytes and was gradu-
Table I. The Expression of EGFP Reporter in enh-EGFP 
Transgenic Mice
Founder
Transgene
copy
number
Percent
positive
Fluorescence
intensity
enh-EGFP
I 1 18 37
II 2 10 111
III 2 43 1,245
IV 2 67 3,858
V 2 94 2,151
VI 8 82  9,000
enh/Amut-EGFP
I2  1  
II 4  1  
III 6  1  
IV 9 98 4,362
V1 0  1  
VI 11 19 248
Transgenic thymocytes were analyzed by four-color flow cytometry,
and data for DN3 subset are presented. The percentage of EGFP-
positive cells and the mean fluorescence intensity of the positive peak
were determined using fixed fluorescence detector settings. The
intensity of the control negative peak was 2. In the enh-EGFP founder
VI, the intensity was above the detection range for the given settings.
Figure 2. The expression profile of EGFP reporter driven by pTa ge-
nomic fragments. Lymphocytes from transgenic mice were analyzed by
multicolor flow cytometry, and histograms of green fluorescence in the
indicated lymphocyte subsets are shown. The green fluorescence ob-
served in the BAC enh-EGFP mice is identical to that of the wild-type
mice, revealing no detectable EGFP expression. The top panel represents
subpopulations of DN thymocytes, the middle panel represents subsets of
thymocytes and peripheral T cells, and the bottom panel represents devel-
oping (bone marrow) and mature (splenic) B cells. The lymphocyte sub-
sets were defined as follows: thymic DN (CD3 CD4 CD8 ), ISP
(CD3 CD4 CD8 ), large DP (large CD3 CD4 CD8 ), small DP
(small CD3 /lowCD4 CD8 ), SP (CD3highCD4 CD8   and CD3high
CD4 CD8 ), splenic T cells (CD3high), splenic B cells (B220 CD3 ),
and bone marrow B cells (B220 CD19 ). For thymic DN subsets, thy-
mocytes were stained with a lineage cocktail (CD3/CD4/CD8/B220/
Mac1), and lineage-negative cells were gated as DN1 (CD44 CD25 ),
DN2 (CD44 CD25 ), DN3 (CD44 CD25 ), and DN4 (CD44 
CD25 ).983 Reizis and Leder
ally decreasing during thymocyte maturation into ISP, large
DP, small DP, and SP thymocytes. Importantly, mature pe-
ripheral T cells manifested a dramatic downregulation of
EGFP compared with thymocytes, whereas cells of other
lineages such as developing and mature B cells were com-
pletely EGFP negative. These data suggest that the pTa en-
hancer, in conjunction with its cognate promoter, can
specify expression pattern similar to that of the 85 kb pTa
genomic clone and of the pTa itself. Therefore, the en-
hancer appears sufficient for the correct tissue- and stage-
specific expression of pTa.
The only discrepancy between the observed versus the
expected EGFP expression pattern was the lack of major
EGFP downregulation in SP thymocytes and the presence
of a minor fraction of peripheral T cells bearing trace lev-
els of EGFP. Because such delayed EGFP downregulation
was also observed in BAC-EGFP transgenic mice, it is
likely to be caused by the unusual stability of EGFP rather
than by an improper regulation of expression. Indeed, the
DP/SP transition may not involve extensive proliferation
occurring at the earlier differentiation steps, thus prevent-
ing EGFP dilution by cell division. To directly address
this point, we created transgenic mice bearing an alterna-
tive reporter, the human CD25 protein. This reporter
does not interfere with mouse lymphoid development
(31) and can faithfully reproduce transgene downregula-
tion in mature B lymphocytes (35). As shown in Fig. 3 A,
we placed a larger pTa enhancer fragment or the core en-
hancer (constructs enh-hCD25 and core-hCD25, respec-
tively) upstream of the pTa promoter driving hCD25
minigene expression.
As expected, in the absence of insulator elements these
constructs were subject to severe position effects. Thus, 3
out of 8 enh-hCD25 founders and only 1 out of 10 core-
hCD25 founders manifested detectable hCD25 expression
in the thymus, the fraction of positive cells ranging widely
between the founders. Nevertheless, the hCD25 expression
patterns of both reporter constructs were similar and highly
specific for immature thymocytes. As shown in Fig. 3 B,
hCD25 expression was confined to CD3 /low thymocytes,
while CD3high mature thymocytes were largely hCD25
negative. Accordingly, multicolor staining revealed hCD25
expression in DN and DP but not SP thymocytes, as illus-
trated in Fig. 3 C for the core-hCD25 founder. Moreover,
no expression whatsoever could be detected in mature pe-
ripheral T cells or in other cell types in the spleen and bone
marrow. We conclude that the pTa enhancer and promoter
can properly downregulate the reporter expression in SP
thymocytes and peripheral T cells, consistent with their
primary role in determining the specificity of pTa expres-
sion.
The Enhancer Is Conserved between Mice and Humans. To
confirm the importance of enhancer in the regulation of
pTa expression, we examined its conservation across differ-
ent species. To this end, we compared the sequence up-
stream of the mouse pTa gene (36) with the recently com-
pleted sequence of the human PTA locus. As shown in Fig.
4 A, the comparison revealed a conserved putative en-
hancer fragment located at the same position in the human
gene. No other significant homology regions (except ex-
ons) were observed within the available sequences. Fig. 4 B
illustrates the high degree of homology between the mouse
and human enhancer fragments ( 60% identity in a 0.3 kb
region). As demonstrated in Fig. 4 C, the human enhancer
was active in a mouse pre-T cell line, albeit to a lesser ex-
tent than the homologous mouse enhancer fragment. A
similarly weaker activity of the human enhancer was ob-
served in the human T cell line MOLT4 (data not shown).
The apparently lower intrinsic strength of the human en-
hancer may result from sequence divergence at its 3  end,
where activating sites are located in the mouse enhancer
(28). Overall, the observed strong evolutionary conserva-
Figure 3. The expression profile of hCD25 reporter driven by pTa
regulatory regions. (A) Map of the transgenic constructs used. The con-
structs contained a larger enhancer fragment (enh-hCD25) or the core
enhancer (core-hCD25) upstream of the pTa promoter and human CD25
(hCD25) minigene. (B) Expression of the hCD25 reporter in transgenic
mice. Lymphocytes were analyzed by two-color flow cytometry using
mAb to hCD25 and to CD3 or B220. Shown are dot plots of thymocytes
from two enh-hCD25 founders and a single core-hCD25 founder, and
representative dot plots of splenocytes and bone marrow (BM) cells from
an enh-hCD25 founder. (C) Expression of the hCD25 reporter in thy-
mocyte subsets of the core-hCD25 transgenic founder. Lymphocytes
were stained with mAb to CD4, CD8, and hCD25, and the histograms of
hCD25 fluorescence in DN (CD4 CD8 ), DP (CD4 CD8 ), and SP
(CD4 CD8  and CD4 CD8 ) thymocytes are shown. The percentage
of hCD25-positive cells in each subset is indicated; the nontransgenic
controls contained  0.4% positive cells in each subset.984 The Analysis of pTa Enhancer
tion of the upstream pTa enhancer confirms its central role
in the regulation of pTa gene expression.
The Enhancer Contains a Critical Binding Site for c-Myb.
We have shown previously that a 19-bp deletion at the 5 
end of the enhancer core decreased its activity. The deleted
site, termed site A, contained a sequence imperfectly
matching the consensus binding site for the transcription
factor c-Myb (Fig. 5 A). Genomic footprinting of the en-
hancer revealed a footprint corresponding to the putative
c-Myb site (unpublished data). Moreover, the c-Myb site is
perfectly conserved in the human enhancer (Fig. 4 B). To
confirm the binding of c-Myb to site A, we conducted
electrophoretic mobility shift assay (EMSA) using an in
vitro translated complete c-Myb DNA-binding domain
(DBD). Fig. 5 B illustrates binding of c-Myb DBD to the
probes containing native site A, site A mutated in the pre-
dicted c-Myb binding core, or a consensus c-Myb binding
site. Native, but not mutated site A formed a complex with
the c-Myb DBD, while the synthetic consensus probe
manifested stronger binding. Similarly, in a competition as-
say, the site A probe competed for the c-Myb binding at
higher concentration than the consensus probe, whereas
mutated site A or unrelated probes failed to compete at all
(data not shown). These data suggest that the c-Myb DBD
can specifically bind to site A, apparently with a lower af-
finity than to a consensus c-Myb binding site.
To test the involvement of c-Myb in the activity of site
A, we introduced the same mutation into two enhancer
fragments: a full-strength minimal enhancer and a partially
disabled fragment truncated at the 3  end. Fig. 5 C demon-
strates that the mutation decreased the activity of both frag-
ments in a pre-T cell line, causing the same effect as the de-
letion of site A. To confirm the in vivo importance of the
c-Myb binding site, we introduced the same mutation into
the enh-EGFP transgenic reporter construct, yielding con-
struct enh/Amut-EGFP. As shown in Table I, only two
out of six transgenic founders expressed the mutated con-
struct, compared with six out of six for the native con-
struct. The expression pattern in the two enh/Amut-EGFP
founders expressing EGFP was indistinguishable from that
in enh-EGFP founders. Notably, the expression was ob-
served only in the founders with high transgene copy num-
ber, and did not reach the level observed in the enh-EGFP
founder with a comparable copy number. Thus, the muta-
tion drastically decreased the frequency, and possibly the
level, of the enhancer-driven reporter expression in trans-
genic mice. Altogether, these data suggest that the intact
c-Myb binding site is critical for the optimal activity of the
pTa enhancer.
We observed previously that the pTa enhancer is pref-
erentially active in the pTa-positive pre-T cell line LR1
compared with the pTa-negative T cell line BW5147. To
test whether site A contributed to enhancer specificity,
we transfected reporter constructs containing one or four
copies of 17 bp site A upstream of an SV40 promoter into
LR1 and BW5147 cells. As demonstrated in Fig. 6 A, site
Figure 4. Identification of the human PTA en-
hancer. (A) Sequence comparison of the mouse and
human  pTa loci. The mouse (14 kb; GenBank/
EMBL/DDBJ entries AF132612 and U27268) and
human (20 kb; positions 25,001–45,000 of Gen-
Bank/EMBL/DDBJ entry HS475N16) sequences
were aligned using BLAST 2 Sequences software
(reference 49) with 20 bp window. Shown is the
graphic output of BLAST 2 comparison highlight-
ing conserved regions. (B) Alignment of the mouse
(top) and human (bottom) enhancer sequences.
The enhancer core as defined by deletion analysis
(reference 28) is shown in uppercase letters. The
position of a functional 5  enhancer site (site A) is
indicated, and a putative c-Myb binding site is
boxed. (C) Activity of the human enhancer in pre-T
cells. Constructs containing a 0.25 kb mouse pTa
enhancer or a homologous human fragment up-
stream of SV40 promoter/LacZ were transiently
transfected into the pre-T cell line LR1, and  -galac-
tosidase activity was determined.985 Reizis and Leder
A reporter constructs caused stronger promoter induction
in LR1 cells, in contrast to the control CD3  enhancer.
Accordingly, analysis of c-Myb protein expression in
these cell lines revealed high c-Myb levels in LR1 cells
compared with scarcely detectable levels in BW5147 cells
(Fig. 6 B).
To confirm the correlation between c-Myb expression
and site A activity, we stably overexpressed c-Myb cDNA
in BW5147 cells. As shown in Fig. 6 C, BW5147 clones
overexpressing c-Myb supported higher activity of the
multicopy site A reporter. Altogether, four c-Myb–express-
ing clones were tested with similar results. To ascertain that
the activation of site A was occurring through the c-Myb
binding site, we tested reporters containing four copies of
13 bp site A upstream of a TATA box and luciferase gene.
Similar to the reporter described above, the 13 bp site A re-
porter was preferentially activated in LR1 cells and in
BW5147 cells expressing c-Myb (Fig. 6 D, and data not
shown). In contrast, site A containing a mutation in the
c-Myb site was not activated, instead repressing the activity
of the minimal promoter. These results confirm the transac-
tivation of site A by c-Myb, and suggest that c-Myb might
regulate the stage-specific activity of the pTa enhancer.
The pTa Promoter Contains an E Box Site Activated by
HEB. Recently, Herblot et al. demonstrated that pTa is
activated by E box-binding transcription factor HEB, and
suggested that the activation occurs through the pTa en-
hancer (27). However, we found that the sequential dele-
tion or simultaneous mutation of E boxes within the en-
hancer had little effect on its activity in a pre-T cell line
(unpublished data). To identify a possible alternative bind-
ing site for HEB in the pTa gene, we aligned the pTa core
promoter region with the homologous human sequence
(Fig. 7 A). In contrast to an overall poor sequence conser-
vation, we noted a conserved site containing two E box el-
ements. As illustrated in Fig. 7 A, we simultaneously intro-
duced a point mutation into each E box. The mutation
significantly decreased the mouse promoter activity in pre-T
cells (Fig. 7 B), confirming the importance of intact E box
elements for the promoter function.
The binding of T cell nuclear proteins to the pTa pro-
moter E box site resulted in the formation of complexes
containing E2A and HEB as revealed by antibody super-
shift experiments (data not shown). To confirm the binding
of HEB to the pTa promoter, we tested the effect of HEB
overexpression on the promoter activity in a pre-T cell
line. As illustrated in Fig. 7 C, transient HEB overexpres-
sion significantly induced the native pTa promoter, appar-
ently because the amount of endogenous HEB in LR1 cells
is not saturating. In contrast, no induction by HEB was ob-
served with the pTa promoter containing the E box site
mutation, or with two control promoters. These data sug-
gest that HEB is likely to activate pTa expression through a
critical E box–containing site in the pTa promoter.
Discussion
This study was aimed at dissecting the regulatory ele-
ments of the pTa gene, which manifests a unique expres-
sion pattern specific for immature T cells. We tested the
function of the upstream pTa enhancer by deleting it from
Figure 5. The binding of c-Myb to the 5  enhancer site (site A). (A)
Sequence of site A aligned to the c-Myb consensus binding sequence (ref-
erence 50) (D   not C, M   A or C, R   A or G, N   any base; the
three bp core sequence is underlined). The mismatch is indicated by an
asterisk. The mutation (mut.) introduced into the putative c-Myb binding
site is shown. (B) Binding of the c-Myb DNA binding domain (DBD) to
site A. In vitro translated B42 domain alone (control) or its fusion with
c-Myb DBD were incubated with labeled oligonucleotides containing a
synthetic consensus c-Myb binding site or native or mutated site A. Pro-
tein-DNA complexes were visualized by EMSA; the arrow indicates a
c-Myb DBD/DNA complex. (C) Effect of the mutation in the c-Myb
binding site on pTa enhancer activity. The mutation or deletion (del.) of
site A was introduced into the full-strength minimal enhancer fragment
(black boxes) or a partially disabled 5  enhancer fragment (gray boxes).
Constructs containing these fragments upstream of SV40 promoter/LacZ
were transiently transfected into the pre-T cell line LR1, and  -galactosi-
dase activity was determined. 986 The Analysis of pTa Enhancer
a large BAC transgene containing a reporter-modified pTa
locus. This approach to the study of lymphocyte-specific
genes was pioneered by Yu et al., who used it to identify
the regulatory elements of the RAG locus (37). We report
that the deletion of the enhancer completely abolished pTa
reporter expression, while similar deletion of another re-
gion had no effect (unpublished data). In a complementary
approach, we tested the specificity of pTa enhancer linked
to its cognate promoter in transgenic mice. Our data sug-
gest that these constructs targeted reporter transgenes spe-
cifically to immature thymocytes in a pattern closely re-
sembling that of pTa itself. Together with its strong
evolutionary conservation described here, these data estab-
lish the enhancer as a critical regulatory element which is
both necessary and sufficient for the correct pTa expres-
sion.
Several T cell–specific regulatory elements have been
shown to function preferentially in developing rather than
mature T cells. The E8III enhancer of the CD8 gene (38)
and a distal genomic element of the RAG locus (37) are
active specifically in DP thymocytes, but apparently not in
the earlier DN T cells. The promoter and intronic en-
hancer of the human ADA gene supports strong reporter
transgene expression in the thymus (39), particularly in im-
mature cortical thymocytes (12). Nevertheless, significant
reporter activity is observed in the spleen and bone mar-
row (39), consistent with the ubiquitous expression of the
ADA gene. The proximal promoter of the p56lck gene was
Figure 6. Activity of the site A in cells overexpressing
c-Myb. (A) Activity of site A in T cell lines. LR1 and
BW5147 cells were transiently transfected with reporters
containing one or four copies of 17 bp site A, or a control
CD3  enhancer (enh.), upstream of SV40 promoter/LacZ.
Data represent ratio of  -galactosidase activities of each re-
porter to the activity of the promoter alone. (B) Expression
of c-Myb protein in T cell lines as determined by Western
blotting. Protein lysates from LR1 and BW5147 lines, as
well as from BW5147 clones stably transfected with c-Myb
cDNA or expression vector alone, were analyzed. The in
vitro translated full-length c-Myb protein was used as a
control (C.). (C) Transactivation of site A in BW5147 cells
overexpressing c-Myb. Two clones expressing c-Myb
cDNA or the empty vector were transiently transfected
with the reporter containing four copies of 17 bp site A,
and the induction of SV40 promoter was determined as
above. A representative transfection with the control
CD3  enhancer is also shown. (D) Activity of the native or
mutated site A. The BW5147 clone overexpressing c-Myb
was transiently transfected with constructs containing a
13 bp site A (either native or harboring a mutation in the
c-Myb binding site) upstream of the SV40 TATA box/
luciferase reporter. The induction or repression of the
TATA box were determined as above.987 Reizis and Leder
shown to direct thymus-specific transgene expression (40).
However, recent transgenic experiments using this pro-
moter suggest that it maintains some activity in mature pe-
ripheral T cells (26, 41, 42). In particular, the EGFP re-
porter driven by lck proximal promoter manifested variably
low levels in DN thymocytes, but equally high levels in
DP thymocytes and in peripheral T cells (41, 42). In con-
trast, the pTa enhancer and promoter supported a pro-
found downregulation of EGFP expression in peripheral T
cells. Moreover, the reporter protein (human CD25) with
an apparently higher turnover rate revealed that the pTa
regulatory elements are downregulated in SP thymocytes
and are completely silent in mature T cells. Such specificity
distinguishes the pTa enhancer and promoter from other
known regulatory elements and warrants further study of
their regulation.
In contrast to the BAC transgenes, the pTa enhancer-
promoter constructs appeared to be strongly influenced by
the site of integration in transgenic mice. The observed po-
sition effects could be partially overcome by the inclusion
of heterologous insulator elements. It is likely that similar
elements located elsewhere in the pTa locus augment its
expression in the context of intact chromatin. Notably, the
large enhancer fragment supported hCD25 transgene ex-
pression at a higher frequency than the core enhancer, al-
though both constructs were equally efficient in transient
transfections (data not shown). This suggests that an ele-
ment modulating chromatin organization might be located
adjacent to the enhancer. Indeed, the upstream DNase-
hypersensitive region corresponding to the pTa enhancer
contained two hypersensitive sites separated by 0.3–0.4 kb
(28). The second site is likely to represent a matrix attach-
ment region (MAR), which are often found in the vicinity
of distal enhancers and can facilitate enhancer function by
increasing chromatin accessibility (43).
Our analysis of the pTa enhancer revealed a binding site
for the transcription factor c-Myb. A member of the tryp-
tophan cluster family of transcription factors, c-Myb is es-
sential for hematopoiesis (44) and was recently found in-
dispensable for lymphoid development, and particularly
for the establishment of the T cell lineage (6). Further-
more, c-Myb appears to regulate proliferation of DN thy-
mocytes after  -selection (45). Important c-Myb binding
sites were found in several T cell–specific regulatory ele-
ments including the CD4 promoter (8) and silencer (46),
TCR  (11) and TCR  (9) enhancers, the ADA enhancer
(12), the lck proximal promoter (10), and the T cell–spe-
cific site within RAG-2 promoter (13). Notably, the latter
three elements are preferentially active in immature T
cells. C-Myb is abundantly expressed in immature cortical
thymocytes (which include DN and DP subsets), but not
in medullary thymocytes (corresponding to SP subset) or
Figure 7. The identification of an E box-containing site within the pTa promoter. (A) Alignment of the mouse (top) and human (bottom) core pro-
moter regions. The major transcription start site of the mouse pTa gene is indicated by an arrow. Two conserved E box elements are boxed; the intro-
duced mutation (E box mut.) is shown at the bottom. (B) Effect of the E box mutation on the promoter activity. LacZ reporter constructs containing the
native or mutated mouse pTa promoter, or a control promoterless construct, were transiently transfected into LR1 pre-T cells, and  -galactosidase activ-
ity was determined. (C) Activation of the pTa promoter after HEB overexpression. The indicated promoter/LacZ constructs were cotransfected with
HEB cDNA-containing or empty expression vectors and a control luciferase reporter into LR1 cells. The induction of  -galactosidase activity in the
presence of HEB as compared with the empty expression vector was determined for each reporter construct after normalization for luciferase activity.
The mean induction   SD of three independent experiments is shown.988 The Analysis of pTa Enhancer
in resting peripheral T cells (7). This pattern is consistent
with the stage-specific expression of pTa in T cells. Impor-
tantly, it has been observed that c-Myb is expressed in
early hematopoietic progenitors as well as in immature T
cells, but not in immature B cells (47). Therefore, c-Myb
is likely to be a major transcriptional activator in immature
T cells, and may regulate both the stage- and tissue-spe-
cific gene expression.
Consistent with this notion, the c-Myb binding site is
perfectly conserved in the mouse and human enhancer. In
contrast, this site is completely deleted in the nonfunctional
pTa enhancer homologue located at the mouse X chromo-
some, which otherwise exhibits high sequence identity
with the enhancer (36). Indeed, the mutation of the c-Myb
site in the pTa enhancer decreased both the enhancer activ-
ity in vitro and the frequency of transgene expression in
vivo. The partial effect of the mutation can be explained by
the apparently modular rather than cooperative nature of
the pTa enhancer, so that even extensive deletions within
the enhancer core do not completely abolish its activity
(28). A similar decrease in the frequency of expression,
with the minority of founders expressing nearly normal
transgene levels, was observed following the mutation of a
critical c-Myb binding site in the ADA enhancer (12).
Thus, the c-Myb sites in these elements, although not ab-
solutely required for the expression, appear to increase the
probability of enhanceosome assembly and of efficient tran-
scription. In transgenic analysis, this may manifest itself as
the ability to overcome position effect variegation and to
increase the frequency of expression. Although the muta-
tion in the c-Myb site apparently did not alter the specific-
ity of the pTa transgene expression, we here show that
c-Myb may contribute to the preferential pTa enhancer ac-
tivity in immature T cell lines. These data, together with
the presence of c-Myb in the developing but not in mature
T cells, suggest that c-Myb might regulate the stage-spe-
cific expression of pTa.
In contrast to the majority of c-Myb binding sites de-
scribed to date, the site in both mouse and human pTa en-
hancers contains a mismatch to the c-Myb consensus se-
quence and accordingly manifested lower binding capacity.
Such an imperfect binding site may have arisen by chance,
if its low affinity is sufficient for activation in the context of
the pTa enhancer. Alternatively, a low-affinity binding site
might require a higher concentration of c-Myb in the nu-
cleus and consequently might render the enhancer more
sensitive to c-Myb downregulation during T cell matura-
tion. Be that as it may, these results call attention to the role
of nonconsensus binding sites in transcriptional regulation.
Recently, pTa was shown to be activated by E proteins
(22) and specifically by HEB (27), although the site of E
protein activity has not been determined. We here identify
a conserved tandem E box element within the pTa pro-
moter, which could be activated by HEB. The mutation of
this site decreased the promoter activity in pre-T cells,
whereas the mutation of E boxes within the enhancer had
no effect (unpublished data). Moreover, the tandem E box
element in the promoter resembles a critical tandem E box
site in the CD4 enhancer, a prototype target of E2A/HEB
heterodimers in T cells (48). Thus, the promoter is likely
to be a primary target for pTa upregulation by E proteins
in immature T cells. Indeed, HEB is abundantly expressed
in thymocytes, particularly in DN and DP rather than SP
subsets (27). Moreover, the dynamic changes of bHLH
protein complexes binding to this site, such as the displace-
ment of SCL/LMO1 by HEB-containing complexes dur-
ing T cell commitment, may contribute to the specificity
of pTa expression.
In conclusion, we show that the pTa enhancer is a criti-
cal element regulating pTa expression in T cells. Moreover,
in combination with the pTa promoter, the enhancer dis-
plays a unique specificity for immature T cells, displaying
the highest activity in the DN population. These results es-
tablish a useful model for dissecting the transcriptional
pathways involved in early T cell development and lineage
commitment, such as the induction of pTa by Notch sig-
naling (26). For practical purposes, the pTa regulatory ele-
ments described here may be useful for the targeting of
transgenes specifically to immature T lymphocytes.
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